Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Benzinga
- Trial Success: Alumis Inc. achieved all primary and secondary endpoints in its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, resulting in a 132% surge in stock price, indicating strong market potential and investor confidence.
- Market Reaction: Following the announcement, shares skyrocketed to $19.30, reflecting a positive investor response to the clinical data, which may attract more institutional investors and further enhance the company's market capitalization.
- Industry Impact: Alumis's success provides a new treatment option in the biopharmaceutical industry, particularly in the psoriasis sector, potentially prompting other companies to increase R&D investments and drive overall industry innovation.
- Future Outlook: With the successful clinical trials, Alumis is expected to accelerate the drug's market entry, likely leading to significant revenue growth while strengthening its position in the highly competitive biopharmaceutical market.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ALMS
Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 37.67 USD with a low forecast of 32.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.710
Low
32.00
Averages
37.67
High
50.00
Current: 27.710
Low
32.00
Averages
37.67
High
50.00
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysts Bullish on Century Communities, Target Price Set at $92
- Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
- Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
- Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
- Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.
Continue Reading
Alumis Director Srinivas Akkaraju Purchases 588,235 Shares for ~$10 Million
- Large Transaction: On January 9, 2026, Srinivas Akkaraju purchased 588,235 shares of Alumis at $17 per share for a total of approximately $10 million, marking one of the largest trades in his history and exceeding the historical median trade size by nearly 47%.
- Increased Indirect Holdings: Following this transaction, Akkaraju's indirect holdings rose to 1,853,488 shares, reflecting his confidence in Alumis's future growth, particularly as the company's stock has surged over 400% in the past year.
- Market Price Comparison: The acquisition price was below the market open of $18.50 and close of $19.56 on January 9, 2026, indicating a favorable entry point for Akkaraju ahead of subsequent price increases, suggesting expectations of further appreciation.
- Clinical Trial Success: Alumis recently reported that 65% of patients in two Phase 3 trials with envudeucitinib achieved a 90% or better improvement in their psoriasis area and severity index (PASI) scores, indicating superior efficacy compared to Amgen's Otezla, further boosting market confidence in its products.
Continue Reading